DERINAT spray 0.25% 10ml

Nosological classification (ICD-10)

E14.5 Diabetic ulcer
H10.9 Conjunctivitis, unspecified
H57.9 Disorder of the eye and adnexa, unspecified
I73.9 Peripheral vascular disease, unspecified
I84 Hemorrhoids
I87.2 Venous insufficiency (chronic) (peripheral)
J00 Acute nasopharyngitis [runny nose]
J01 Acute sinusitis
J01.0 Acute maxillary sinusitis
J01.1 Acute frontal sinusitis
J01.9 Acute sinusitis, unspecified
J06 Acute upper respiratory tract infections of multiple and unspecified localization
J31.0 Chronic rhinitis
J32 Chronic sinusitis
J32.0 Chronic maxillary sinusitis
J32.1 Chronic frontal sinusitis
J32.9 Chronic sinusitis, unspecified
K12 Stomatitis and related lesions
K13.7 Other and unspecified lesions of the oral mucosa
L58 Radiation radiation dermatitis
L98.4.2* Trophic skin ulcer
N76 Other inflammatory diseases of the vagina and vulva
R02 Gangrene, not elsewhere classified
T14.1 Open wound of unspecified body area
T30 Thermal and chemical burns of unspecified location
T35 Frostbite involving multiple areas of the body and unspecified frostbite

Pharmacodynamics

The drug activates cellular and humoral immunity. Optimizes specific responses against fungal, viral and bacterial infections. The drug stimulates reparative and regenerative processes, normalizes the condition of tissues and organs in dystrophies of vascular origin. Derinat® promotes the healing of trophic ulcers of various etiologies, as well as the rapid healing of deep burns, significantly accelerating the dynamics of epithelization. When ulcerative formations on the mucous membrane are restored under the influence of the drug, scarless restoration occurs. Derinat® does not have teratogenic or carcinogenic effects.

Indications for the drug Derinat®

Monotherapy:

acute respiratory infections;

prevention and treatment of ARVI;

ophthalmology - inflammatory and dystrophic processes;

inflammatory diseases of the mucous membranes of the oral cavity.

Complex therapy:

chronic inflammatory diseases, fungal, bacterial and other infections of the mucous membranes in gynecology;

acute and chronic diseases of the upper respiratory tract (rhinitis, sinusitis, sinusitis, sinusitis);

obliterating diseases of the lower extremities;

trophic ulcers, long-term non-healing and infected wounds (including diabetes mellitus);

gangrene;

burns, frostbite;

haemorrhoids;

post-radiation necrosis of the skin and mucous membranes.

Indications for use

The drug is used as a primary and additional medicine. In the first case, Derinat is used to treat infectious diseases (external use):

ARVI (including for prevention purposes);
inflammatory ophthalmological pathologies, including those with purulent discharge;
inflammation of the oral mucosa.

The drug is also used as an additional remedy as part of the complex treatment of such pathologies (external use):

inflammatory processes (chronic);
gynecological infections of a bacterial or fungal nature;
acute and chronic pathologies of the nasal sinuses, including sinusitis, rhinitis;
wounds and ulcers that do not go away for a long time, including due to the development of diabetes mellitus;
gangrene;
burns of varying degrees;
haemorrhoids;
partial death of the skin or mucous membrane;
frostbite.

Injections are given for the treatment of a number of diseases of the cardiovascular, digestive and other organ systems:

ulcers in the gastrointestinal tract;
IHD;
OSC (stages of development: I, II);
long-lasting wounds, burns and other skin damage;
dysfunction of hematopoiesis;
radiation injuries;
myelodepression;
stomatitis of various nature;
rheumatoid type arthritis;
endometritis;
COPD;
prostatitis;
bacterial infections of the genitourinary system, including chlamydia, ureaplasmosis.

Directions for use and doses

Externally, locally.

The drug is prescribed to children from the first day of life and to adults.

To prevent ARVI, instill 2 drops into each nasal passage 2–4 times a day for 1–2 weeks.

For acute respiratory infections, acute respiratory viral infections, the drug is instilled into the nose, 2-3 drops into each nasal passage every 1-1.5 hours, during the first day; further - 2-3 drops in each nasal passage 3-4 times a day, course duration - 1 month.

For inflammatory diseases of the nasal cavity and paranasal sinuses, the drug is instilled 3-5 drops into each nasal passage 4-6 times a day. Course duration is 7–15 days.

For diseases of the oral mucosa, rinse with the drug 4-6 times a day (1 vial - 1-2 rinses). The duration of treatment is 5–10 days.

For chronic inflammatory diseases, fungal, bacterial and other infections in gynecology - intravaginal administration with irrigation of the cervix or intravaginal administration of tampons with the drug, 5 ml per procedure, 1-2 times a day for 10-14 days.

For hemorrhoids, the drug is prescribed as microenemas of 15–40 ml into the rectum. The duration of treatment is 4–10 days.

For severe inflammatory and dystrophic processes in ophthalmology, Derinat® is instilled into the eyes 2-3 times a day, 1-2 drops, for 14-45 days.

For obliterating diseases of the lower extremities, the drug is instilled 1-2 drops into each nasal passage 6 times a day, the course duration is up to 6 months.

For post-radiation necrosis of the skin and mucous membranes, long-term non-healing wounds, burns, frostbite, trophic ulcers of various etiologies, gangrene, application bandages (gauze in two layers) are applied to the affected areas with the drug applied to it 3-4 times during the day (course of treatment - 1–3 months).

Derinat official instructions for use

Pharmacological properties

The drug activates cellular and humoral immunity. Optimizes specific responses against fungal, viral and bacterial infections. The drug stimulates reparative and regenerative processes, normalizes the condition of tissues and organs in dystrophies of vascular origin. The drug Derinat promotes the healing of trophic ulcers of various etiologies. The drug Derinat promotes rapid healing of deep burns, significantly accelerating the dynamics of epithelization. When ulcerative formations on the mucous membrane are restored under the influence of the drug Derinat, scarless restoration occurs. The drug does not have teratogenic or carcinogenic effects.

Pharmacokinetics

Derinat, when applied topically, is quickly absorbed and distributed in organs and tissues via the endolymphatic transport route. During the phase of intensive entry of the drug into the blood, redistribution occurs between plasma and blood cells, in parallel with metabolism and excretion. Derinat is metabolized in the body. It is excreted from the body (in the form of metabolites) partially with feces, and, to a greater extent, with urine according to a biexponential dependence.

Indications for use

Monotherapy:

acute respiratory diseases (ARI);
prevention and treatment of acute respiratory viral infections (ARVI);
inflammatory diseases of the mucous membranes of the oral cavity.

Complex therapy:

chronic inflammatory diseases, fungal, bacterial and other infections of the mucous membranes in gynecology;
acute and chronic diseases of the upper respiratory tract (rhinitis, sinusitis, sinusitis, sinusitis);
obliterating diseases of the lower extremities;
trophic ulcers, long-term non-healing and infected wounds (including diabetes mellitus);
gangrene;
burns, frostbite;
haemorrhoids;
post-radiation necrosis of the skin and mucous membranes.

Contraindications for use

Hypersensitivity to sodium deoxyribonucleate.

Use during pregnancy and breastfeeding

A doctor's consultation is required. If it is necessary to prescribe the drug during pregnancy, the expected benefit to the mother and the potential risk to the fetus should be assessed. During breastfeeding, use as prescribed by a doctor.

Directions for use and doses

The drug is prescribed to children from the first day of life and to adults.

To prevent ARVI, instill 2 drops into the nose or 1 spray into each nasal passage 2-4 times a day for 1-2 weeks.

For acute respiratory infections, acute respiratory viral infections, the drug is instilled into the nose, 2-3 drops in each nasal passage or 1 - 2 sprays in each nasal passage every 1-1.5 hours, during the first day; further - 2-3 drops or 1 spray in each nasal passage 3-4 times a day, course duration - 1 month.

For inflammatory diseases of the nasal cavity and paranasal sinuses, the drug is instilled 3-5 drops or 1-2 sprays into each nasal passage 4-6 times a day. Course duration is 7-15 days.

For diseases of the oral mucosa, rinse with the drug 4 - 6 times a day (1 bottle - 1-2 rinses) or the drug is evenly sprayed onto the corresponding damaged areas of the mucous membrane, 2 - 3 sprays 4-6 times a day. The duration of treatment is 5-10 days.

For hemorrhoids, the drug is prescribed as microenemas of 15-40 ml into the rectum. The duration of treatment is 4-10 days.

For obliterating diseases of the lower extremities, the drug is instilled into the nose, 1-2 drops in each nasal passage 6 times a day, course duration is up to 6 months. For post-radiation necrosis of the skin and mucous membranes, for long-term non-healing wounds, burns, frostbite, trophic ulcers of various etiologies, gangrene, application bandages (gauze in two layers) are applied to the affected areas with the drug applied to it 3-4 times during the day or treatment is carried out the affected surface with the drug from a nebulizer 4-5 times a day, 10 - 40 ml (course of treatment - 1-3 months).

Side effect

In case of gangrenous processes under the influence of the drug, spontaneous rejection of necrotic masses in the foci of rejection is observed with restoration of the skin. For open wounds and burns, an analgesic effect is observed. If you notice any other side effects not listed in the instructions, tell your doctor. If you notice any other side effects not listed in the instructions, tell your doctor.

Overdose

No cases of overdose have been reported.

Interaction with other drugs

When applied topically, it is not compatible with fat-based ointments and hydrogen peroxide.

Impact on the ability to drive vehicles and machinery

The use of the drug Derinat® does not affect the ability to perform potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions (including driving vehicles, working with moving mechanisms).

Release form

Solution for local and external use 0.25%. 10 ml in bottles made of colorless or brown glass, hermetically sealed with rubber stoppers and rolled in aluminum caps. 10 ml in dropper bottles made of colorless or brown glass, hermetically sealed with pipette caps equipped with a first opening control device. 10 ml in bottles made of colorless or brown glass, sealed with horizontal or vertical spray nozzles, equipped with protective caps. A bottle or dropper bottle or a bottle with a spray nozzle, with instructions for medical use, is placed in a pack of cardboard boxes.